“The past 12 months have seen landmark achievements for
In the last 12 months,
Clinical
- Dosed additional NXC-201 patients: totaling 10 relapsed/refractory AL Amyloidosis patients and 63 relapsed/refractory multiple myeloma patients, presented at the 65th annual ASH conference in
San Diego, CA
Regulatory
- Received
U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) for NXC-201 treatment ofU.S. patients - Received FDA Orphan Drug Designation (ODD) for the treatment of AL Amyloidosis
- Received FDA Orphan Drug Designation (ODD) for the treatment of multiple myeloma
- Received EU Orphan Drug Designation (ODD) for the treatment of AL Amyloidosis
Expanded Scientific Advisory Board Membership
Heather Landau , MD - Memorial Sloan Kettering Amyloidosis Program DirectorMichaela Liedtke , MD - Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid CenterSuzanne Lentzsch , MD - Director of the Multiple Myeloma and Amyloidosis Program at theCollege of Physicians andSurgeons of Columbia University and atNew York Presbyterian Hospital Marko Radic , PhD - Autoimmune CAR-T Pioneer and Associate Professor at theUniversity of Tennessee Health Science Center Vaishali Sanchorawala , MD – Skinner Professor ofAmyloidosis Research in theDepartment of Medicine atBoston University Chobanian & Avedisian School of Medicine , and Director of the Amyloidosis Center atBoston Medical Center (BMC) andBoston University
Expanded Team
- Dr.
Gerhard Bauer , head of cell therapy manufacturing, with more than two decades of experience in design, manufacturing, and operation of GMP cell therapy manufacturing facilities and numerous investigational new drug (IND) applications to FDA David Marks , MBBS, PhD, chief medical officer, cell therapy, who was appointed by regulators as a clinical expert in 2 CAR-T regulatory approvals: KYMRIAH® and TECARTUS®Henry A. McKinnell , former Pfizer CEO;Mary Sue Coleman , former Johnson & Johnson Director;Jeffrey Cooper , former BioMarin CFO;Edward Borkowski , former Mylan CFO, who along with existing directorHelen Adams have participated in close to$20 billion inU.S. pharmaceutical mergers & acquisitions- Additional team members across business development, regulatory, clinical and research & development staff
- ASH - 65th Annual
American Society of Hematology Annual Meeting and Exposition (AL Amyloidosis) -Dec 10, 2023 Oral Presentation - ASH - 65th Annual
American Society of Hematology Annual Meeting and Exposition – (AL Amyloidosis) – 2023 Abstract - IMS -
International Myeloma Society - 20th Annual Meeting - Oral Presentation (AL Amyloidosis) -Sep 27-30, 2023 Oral Presentation - ASGCT –
American Society of Gene & Cell Therapy — 29th Annual Meeting –May 19, 2023 Oral Presentation (Late-Breaking) - ASGCT –
American Society of Gene & Cell Therapy — 29th Annual Meeting –May 19, 2023 Late-Breaking Abstract
- ASH - 65th Annual
American Society of Hematology Annual Meeting and Exposition – (Multiple Myeloma) -Dec 11, 2023 Poster Presentation - ASH - 65th Annual
American Society of Hematology Annual Meeting and Exposition – (Multiple Myeloma) – 2023 Abstract - IMS -
International Myeloma Society - 20th Annual Meeting - (Multiple Myeloma) -Sep 27-30, 2023 Poster Presentation European Society for Blood and Marrow Transplantation 49th Annual Meeting – 58 Patient Clinical Data Poster Presentation –Apr 23-26, 2023 Poster Presentation- 5th European CAR T-cell Meeting – 42 Patient Clinical Data Poster Presentation –
Feb 9-11, 2023 Poster Presentation - Publication: Asherie N,
Kfir-Erenfeld S , Avni B, Assayag M, Dubnikov T, Zalcman N, Lebel E, Zimran E, Shaulov A, Pick M, Cohen Y, Avivi I, Cohen C, Gatt ME, Grisariu S,Stepensky P. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023Jul 1 ;108(7):1827-1839. doi: 10.3324/haematol.2022.281628. PMID: 36200421; PMCID: PMC10316256. - Editorial Publication: Sjöstrand M, Sadelain M. Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. Haematologica. 2023
Jul 1 ;108(7):1721-1723. doi: 10.3324/haematol.2022.282053. PMID: 36794501; PMCID: PMC10316265.
The above publications and presentations are available on the “publications” section of the ImmixBio website.
Investor Events
- Presented at the
Bank of America Healthcare Trailblazers Conference - Presented at the JMP Securities Hematology and Oncology Summit
- Hosted a Key Opinion Leader (KOL) event discussing NXC-201 for the treatment of relapsed/refractory AL Amyloidosis (
November 29 2023 )
Immix Biopharma Annual Letter to Shareholders
Greetings and best in 2024 to you, colleagues and families from the Immix Biopharma Team. As we reflect on the last 12 months of progress, we wish to connect with you offering an update on
We are excited to share remarkable progress at
In addition, we plan to continue our success in the
We must credit our team’s tireless efforts for their advancement of our clinical programs, and are grateful to our board of directors, scientific advisory board members, and team members who have supported
We are grateful for the unwavering support of our investors, collaborators and the tireless effort of our team and look forward to providing ongoing updates during the next 12 months through investor communications, scientific symposia and medical meetings.
Best Regards,
CEO & CFO,
About
Forward Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results, continuing development of our product candidates, including development timelines, timing of FDA submissions and expected endpoints, long-term visions and strategies, evaluations and judgements and beliefs regarding potential efficacy and safety of our product candidates, future clinical development of our product candidates, including any implication that results or observations in initial data, data observed to date, or earlier clinical trials will be representative of results or observations in later data or clinical trials, the expected timing of such results and the potential market size and benefits for our product candidates. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; that our product candidates may not realize the anticipated responses discussed in this release or that their development may suffer delays that materially and adversely affects future commercial viability; that the market for our product candidates may not grow at the rates anticipated or at all; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report on Form 10-K for the year ended
Contacts
mmoyer@lifesciadvisors.com
Company Contact
irteam@immixbio.com
Source:
2024 GlobeNewswire, Inc., source